TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...

Roivant Sciences Ltd. has a 12 month low of $8.47 and a 12 month high of $13.06. The company has a market capitalization of $8.53 billion, a P/E ratio of 2.07 and a beta of 1.24.

Roivant Sciences ( (ROIV) ) has shared an update. Organon has successfully acquired Dermavant Sciences, expanding its dermatology portfolio ...

Roivant Sciences Ltd., a prominent biopharmaceutical company listed on the NASDAQ under the ticker symbol ROIV, recently disclosed a significant development in its operations. As per an 8-K filing ...

On Wednesday, JPMorgan reaffirmed its confidence in Roivant Sciences (NASDAQ:ROIV) shares, maintaining an Overweight rating and a $16.00 price target on the stock. Following a recent meeting with ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other promising ...

Eric Venker, President and COO of Roivant Sciences Ltd. (NASDAQ:ROIV), recently executed a significant transaction involving the company's common shares. On October 21, Venker sold 100,000 shares ...

A substantial insider activity was disclosed on October 23, as Venker, President & COO at Roivant Sciences ROIV, reported the exercise of a large sell of company stock options. What Happened ...

Leerink Partners maintained their Outperform rating on Roivant Sciences (NASDAQ:ROIV) with a steady price target of $17.00. The firm's analyst highlighted Roivant's executive incentive compensation ...

In this article, we are going to take a look at where Roivant Sciences (NASDAQ:ROIV) stands against other high growth UK stocks to invest in. According to a KPMG report, the United Kingdom’s GDP ...